NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APTX stock has increased by 70.8% and is now trading at $4.15.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aptinyx.

Aptinyx will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Aptinyx Inc (NASDAQ:APTX) announced its earnings results on Thursday, May, 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.01. The company earned $0.82 million during the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%.
View Aptinyx's earnings history.

6 brokerages have issued 1 year price targets for Aptinyx's stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Aptinyx's share price to reach $9.67 in the next year. This suggests a possible upside of 132.9% from the stock's current price.
View analysts' price targets for Aptinyx.

Press coverage about APTX stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aptinyx earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Aptinyx.

Aptinyx saw a decrease in short interest in July. As of July 15th, there was short interest totaling 912,900 shares, a decrease of 10.5% from the June 30th total of 1,020,000 shares. Based on an average daily trading volume, of 421,500 shares, the days-to-cover ratio is currently 2.2 days. Approximately 4.1% of the company's shares are sold short.
View Aptinyx's Current Options Chain.

Some companies that are related to Aptinyx include Vectura Group (VEGPF), Assembly Biosciences (ASMB), Omeros (OMER), Legend Biotech (AMTI), Tricida (TCDA), Morphic (MORF), ImmunoGen (IMGN), Frequency Therapeutics (FREQ), Akouos (AKUS), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), ORIC Pharmaceuticals (ORIC), Passage Bio (KROS), Stemline Therapeutics (STML) and Homology Medicines (FIXX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.45%), Meridian Wealth Management LLC (0.07%), Leap Investments LP (0.03%) and UBS Group AG (0.02%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen.
View institutional ownership trends for Aptinyx.

APTX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meridian Wealth Management LLC, Leap Investments LP, and UBS Group AG. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen.
View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $4.15.

Aptinyx has a market capitalization of $189.49 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]